Self-Reported Survey Data: Fast & Reliable, or Imprecise & Risky? inudgeyou.com March 27, 2024, 4:32 p.m.
Human beings are creatures of habit. Ours days have a particular rhythm to them, and behaviours we exhibit today are generally indicative of how we behaved yesterday and will behave tomorrow. Yet for how routine our lives can be, behavioural research conducted the last 50 years has found that people tend to struggle when asked to recall specific details about their day-to-day life.
Mechanism of traditional Chinese medicine in elderly diabetes mellitus and a systematic review of its clinical application www.frontiersin.org March 25, 2024, 3:54 p.m.
Affected by aging, the elderly diabetes patients have many pathological characteristics different from the young people, including more complications, vascular aging, cognitive impairment, osteoporosis, and sarcopenia. This article will explore their pathogenesis and the mechanism of Traditional Chinese medicine (TCM) intervention, and use the method of systematic review to evaluate the clinical application of TCM in elderly diabetes.
Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease www.nature.com March 25, 2024, 3:44 p.m.
Balancing the safety and efficacy of antithrombotic therapy in patients with gastrointestinal disorders is challenging because of the potential for interference with the absorption of antithrombotic drugs or for an increased risk of bleeding. Various clinical states, including malabsorption syndromes, bariatric surgery, short-bowel syndrome or enteral tube feeding, can influence the absorption and bioavailability of oral antithrombotic agents. Bleeding events are an essential prognosticator in patients with cardiovascular diseases — at times as important as thrombotic events — and using antithrombotic agents in patients at high risk of gastrointestinal bleeding (GIB) is very challenging. Most of the existing models to predict the risk of bleeding in patients with coronary artery disease do not estimate the risk of GIB specifically. Identifying patients at high risk of GIB, modifying the bleeding risk by using gastroprotective agents, and determining the appropriate antithrombotic therapy regimen have crucial roles in preventing GIB. After an episode of acute GIB, determining the duration of antithrombotic therapy interruption and the regimen for re-initiation requires consideration of the balance between the bleeding severity and the risk of thrombotic events.
Evaluating Plastic Syringes Made in China for Potential Device Failures: FDA Safety Communication www.fda.gov March 24, 2024, 10:13 a.m.
The U.S. Food and Drug Administration (FDA) is providing an update on our ongoing evaluation of quality and performance issues related to plastic syringes made in China, and announcing additional recommendations and actions the FDA is taking to address these issues.
Exosome Therapeutics Are Paving a Path to Clinical Readiness www.biospace.com March 11, 2024, 7:03 p.m.
Experts are divided on whether or not exosomes are ready to be used as therapeutics. Theresa Whiteside, a professor of immunology at the University of Pittsburgh who studies the use of exosomes as tumor biomarkers, does not believe exosome-based therapeutics are ready for clinical study. “We have no idea what regulates [exosome biology],” Whiteside told BioSpace. “At the moment, it's a confusing picture.” In the other camp, Sharanjot Saini, an associate professor in the department of biochemistry and molecular biology at Augusta University, is using exosomes to deliver drugs for neuroendocrine prostate cancer. Exosomes engineered by Saini’s lab to specifically deliver two drugs to the prostate “significantly” reduced tumor growth in mouse studies. Saini told BioSpace that if initial safety and toxicity tests are conducted with rigor, there is nothing standing in the way of using exosomes as therapeutics.
How Food-as-Medicine Execs Are Responding to Kellogg CEO’s ‘Let Them Eat Flakes’ Remarks medcitynews.com March 5, 2024, 5:45 p.m.
Kellogg CEO Gary Pilnick recently encouraged families struggling to put food on the table to turn to cereal as their go-to dinner option. Food-as-medicine executives are none too thrilled about his comments — they argue that the remarks underscore the dire need to increase public education about affordable, healthy meal planning.
AstraZeneca Loses Lawsuit Challenging Drug Price Negotiation by Medicare medcitynews.com March 4, 2024, 3:57 p.m.
A federal judge disagreed with AstraZeneca’s claims that the Inflation Reduction Act causes harm by disincentivizing innovation and violates its constitutional rights to due process. Blockbuster AstraZeneca drug Farxiga is one of 10 medications selected for the Medicare drug price negotiation program created by the law.
Doctors have started prescribing a new medical treatment: a walking app thenextweb.com March 4, 2024, 7:39 a.m.
Sustainable activity startup Walk15 is launching a steps prescription pilot with the Šeškinės clinic in Vilnius
Zocdoc Launches Tool To Help Connect Patients to the Right Providers medcitynews.com March 3, 2024, 5:26 p.m.
About 57% of patients have gone to a doctor’s appointment to discover that the provider was not the right one for their condition, according to new research from Zocdoc. Because of this, the company launched a new tool called Guided Search that helps pair patients with the correct provider.
Navigating the Wellness Frontier: Show Me the Science medcitynews.com March 2, 2024, 6:23 p.m.
Wellness-oriented consumers are seeking products and practices backed not only by promises but by scientific credibility.
5 MedTech Trends to Follow in 2024 www.resonant-link.com March 1, 2024, 7:40 p.m.
The field of Medical Technology (MedTech) is on an exciting trajectory, with innovations poised to revolutionize healthcare in 2024 and beyond. From cutting-edge medical devices to groundbreaking digital solutions, the intersection of medicine and technology continues to enable a more patient-centric future. Here are five MedTech trends to watch in 2024.
Lower Health Care Costs, Help Inmates. Why Aren’t There PrEP Programs in Prison? medcitynews.com Feb. 29, 2024, 1:32 p.m.
Prisons should offer abundant opportunities for HIV screening and comprehensive pre-exposure prophylaxis (PrEP) adherence programs to benefit incarcerated individuals and carceral systems as a whole.
ICI by Lotan and Beyar awards the winners of the De-Haan med-tech innova www.jpost.com Feb. 27, 2024, 6:29 p.m.
Alchimedics from France won third place, having developed a drug-coated stent that also acts against blood clotting, and reduces the need to administer blood thinners after stent implantation in the coronary arteries. The company was awarded a prize of $20,000.
Lose Fat, Not Muscle: Next Test for Lilly's Zepbound Pairs It With BioAge Drug medcitynews.com Feb. 26, 2024, 2:54 p.m.
In preclinical testing, combining BioAge Labs’ experimental drug with Eli Lilly weight drug Zepbound led to greater weight loss compared with Zepbound alone. Now the company plans to run a Phase 2 study to see if it can replicate those results in humans.
Hypercalcémie familiale bénigne www.filiereorkid.com Feb. 24, 2024, 2:17 p.m.
L’hypercalcémie familiale bénigne est également appelée « hypercalcémie hypocalciurique familiale ». Elle est liée le plus souvent à une mutation inhibitrice du récepteur du calcium (CaR codé par le gène CASR sur le chromosome 3 ; OMIM 14598) définissant l’hypercalcémie hypocalciurique familiale de type 1 ou HHF1.
Adverse Event Prompts FDA Hold on Tests of Drug in Atopic Dermatitis & Asthma medcitynews.com Feb. 21, 2024, 4:32 p.m.
The FDA clinical hold follows a a report of liver failure that may be associated with zelnecirnon, an experimental Rapt Therapeutics drug. The biotech notes that no other patient has experienced liver problems and this safety signal has not been seen in any other tests of the molecule.
A Personalized Approach to Medication Nonadherence medcitynews.com Feb. 21, 2024, 4:30 p.m.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Elation Health’s New Integration Brings Drug Pricing Transparency to the Point of Care for PCPs medcitynews.com Feb. 17, 2024, 2:08 p.m.
Elation Health integrated Surescripts’ real-time prescription benefit tool — which gives clinicians immediate access to patient-specific medication coverage and cost data — into its EHR. The partnership aims to improve patients' medication adherence by helping primary care physicians have more meaningful conversations with their patients about prescription affordability during visits.
Despite Price Transparency Laws, Americans Are Nowhere Near Able to Shop for Care. How Can This Change? medcitynews.com Feb. 15, 2024, 2:08 p.m.
Most hospitals and payers have publicly posted their pricing information, but experts think that data will remain mostly useless for consumers for at least another five years. Now that the data is available, healthcare software companies must step in and build tools that are personalized and easy to use. That way, consumers can eventually use price transparency data to shop for care.